The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone
Roger S McIntyre1,2 1Department of Psychiatry, University of Toronto, 2Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada Abstract: Although many branded and generic antidepressants are approved for the treatment of major depressive disorder (MDD) in Canada, eff...
Saved in:
Main Author: | McIntyre RS |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2017
|
Subjects: | |
Online Access: | https://doaj.org/article/d40558993d764a58a049ed3e652c0a7d |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Selective serotonin reuptake inhibitors may lead to improved cataract surgery outcomes in patients with amblyopia
by: Xin KZ, et al.
Published: (2019) -
A meta-analysis of effects of selective serotonin reuptake inhibitors on blood pressure in depression treatment: outcomes from placebo and serotonin and noradrenaline reuptake inhibitor controlled trials
by: Zhong Z, et al.
Published: (2017) -
The noradrenergic paradox: implications in the management of depression and anxiety
by: Montoya A, et al.
Published: (2016) -
Early symptom non-improvement and aggravation are associated with the treatment response to SSRIs in MDD: a real-world study
by: Yuan H, et al.
Published: (2019) -
Effect of Depression and Antidepressants on Sexual Dysfunction in Men with Diabetes: A National Population-Based Cohort Study
by: Chung PL, et al.
Published: (2020)